Evidence map›Paper›PMID 40303374›Full record

ArticleFrontiers in medicine2025

Global, regional, and national burden of leukemia, 1990-2021: a systematic analysis of the global burden of disease in 2021.

Jiaxi Chen, Wenyi Pang, Miao Deng, Rubin Zheng, Yanjin Chen, Ziyang Zhang, Zhouke Tan, Zhixun Bai

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Global Burden of Chronic Lymphocytic Leukemia From 1990 to 2021.Cancer control : journal of the Moffitt Cancer Center
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaxi Chen *Clinical College, Zunyi Medical University, Zunyi, Guizhou, China.
Wenyi Pang *Clinical College, Zunyi Medical University, Zunyi, Guizhou, China.
Miao DengDepartment of Nephrology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Rubin ZhengClinical College, Zunyi Medical University, Zunyi, Guizhou, China.
Yanjin ChenClinical College, Zunyi Medical University, Zunyi, Guizhou, China.
Ziyang ZhangDepartment of Nephrology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zhouke TanDepartment of Nephrology, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
Zhixun BaiDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, Guizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Leukemia is a heterogeneous hematologic malignancy with varying incidence, mortality, and disability-adjusted life years (DALYs) worldwide. Although the burden of leukemia has declined over recent decades, substantial disparities remain across different regions, socioeconomic levels, age groups, and sexes. This study looks at trends in leukemia cases, deaths, and the impact on quality of life from 1990 to 2021, aiming to uncover inequalities and help design better interventions. Methods: This study extracted data from the Global Burden of Disease (GBD) database (1990-2021) for five types of leukemia. The age-standardized incidence, mortality, and DALY rates for leukemia were calculated for 204 countries and 27 super regions worldwide. The estimated annual percentage change (EAPC) was used to quantify the trends in the leukemia burden, and trends were quantified using estimated annual percentage changes (EAPCs). Decomposition analysis examined the contributions of population growth, aging, and epidemiological changes. Additionally, autoregressive integrated moving average (ARIMA) and age-period-cohort (APC) models were employed. Inequality in leukemia burden was assessed using the Slope Index of Inequality (SII) and Concentration Index (CI). Results: Globally, the incidence and mortality of leukemia increased with age and were consistently higher in males. While incidence and mortality are projected to rise, DALYs are expected to decline slightly by 2031. Acute lymphoid leukemia (ALL) and acute myeloid leukemia (AML) dominated incidence and mortality patterns, with higher ALL burdens in low-SDI regions and more pronounced AML burdens in higher-SDI regions. Decomposition analysis indicated that epidemiological changes and population growth drove trends in incidence and mortality, respectively. APC results showed declining period effects and lower risks in more recent birth cohorts. Inequality analyses revealed a growing disparity in incidence and mortality burdens in high-SDI countries, while DALYs inequality slightly narrowed. Conclusion: From 1990 to 2021, the global burden of leukemia has shifted, with persistent geographic, socioeconomic, and sex-related differences. Although overall improvements in prevention and treatment have reduced the DALYs burden, rising incidence and mortality in certain regions underscore the need for tailored public health strategies, early screening, and risk-based interventions to address persistent health inequalities and mitigate future leukemia burdens.

Indexed as

DALYsglobal burden of diseaseincidenceleukemiamortality

Identifiers

PMID40303374
PMCPMC12037485

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.